‘Renovation of old drugs’ – can peptide drug conjugates lead the post-ADC era?

Peptide–drug conjugates (PDCs) are an emerging targeted therapeutic drug following on from the relative success of antibody–drug conjugates (ADCs). In this class, peptides are used to target payload molecules at the disease sites, thereby reducing toxicity and improving the physicochemical propertie...

Full description

Saved in:
Bibliographic Details
Published in:Critical studies in media communication 2023-06, Vol.76 (8), p.318
Main Authors: Hao, Chaowei, Chen, Peng, Zhang, Hui, Sarra Setrerrahmane, Xu, Hanmei
Format: Article
Language:English
Subjects:
Antibodies
Cancer therapies
Chemotherapy
Conjugates
Drugs
FDA approval
Kinases
Molecular structure
Molecular weight
Peptides
Pharmaceutical industry
Proteins
R&D
Research & development
Side effects
Success
Toxic diseases
Toxicity
Toxins
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Peptide–drug conjugates (PDCs) are an emerging targeted therapeutic drug following on from the relative success of antibody–drug conjugates (ADCs). In this class, peptides are used to target payload molecules at the disease sites, thereby reducing toxicity and improving the physicochemical properties of the payload. A PDC is composed of three parts: peptide, linker and toxin molecule, and in this structure, the selection of the target in addition to the affinity and stability of the peptide are the keys to the success of PDCs. Since the development of ADCs, drugs have undergone several updates – can PDCs leverage the experience and lessons learned from the development of ADCs over the years to achieve new success? This review presents a systematic introduction of each component of PDCs, as well as the characteristics of PDCs under investigation, with the prospect of PDC development to deepen understanding of their mechanism of action.
ISSN:1529-5036
DOI:10.1071/CH22252